Cargando…
Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
Liposomal formulations are hypothesized to alleviate anthracycline cardiotoxicity, although this has only been documented clinically for doxorubicin. We developed an in vitro multiparametric model using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) to assess the relative toxi...
Autores principales: | Fortin, Marie C., LaCroix, Andrew S., Grammatopoulos, Tom N., Tan, Lei, Wang, Qi, Manca, Dino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686991/ https://www.ncbi.nlm.nih.gov/pubmed/38030645 http://dx.doi.org/10.1038/s41598-023-47293-4 |
Ejemplares similares
-
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018) -
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018) -
CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
por: Mayer, Lawrence D, et al.
Publicado: (2019) -
Comparison of Zebrafish Larvae and hiPSC Cardiomyocytes for Predicting Drug-Induced Cardiotoxicity in Humans
por: Dyballa, Sylvia, et al.
Publicado: (2019) -
Does Enhanced Structural Maturity of hiPSC-Cardiomyocytes Better for the Detection of Drug-Induced Cardiotoxicity?
por: Van de Sande, Dieter, et al.
Publicado: (2023)